Moberg Pharma considers an acquisition of a brand from Prestige Brands and evaluates the preconditions for carrying out a directed new shares issue
STOCKHOLM, December 6th, 2016. Moberg Pharma AB (publ) (”Moberg Pharma” or the “Company”) (OMX: MOB) considers an acquisition of DermoPlast®, a well-established Over-the-Counter brand in the U.S., from the Prestige Brands group. If the acquisition is carried out, the purchase price will be USD 47.6M plus stock value. Moberg Pharma has, based on the authorization to issue shares granted by the Company’s annual general meeting on 18 May 2016, mandated Carnegie Investment Bank to assess the preconditions for a private placement of up to 2,843,504 shares, through a so-called “accelerated book-